• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝癌伴肝外转移行肝切除术的临床意义。

Clinical Significance of Hepatectomy for Hepatocellular Carcinoma Associated with Extrahepatic Metastases.

机构信息

Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan,

Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

Dig Surg. 2020;37(5):411-419. doi: 10.1159/000507436. Epub 2020 May 26.

DOI:10.1159/000507436
PMID:32454487
Abstract

BACKGROUND

This study evaluated the prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases who can undergo hepatectomy.

METHODS

A total of 32 patients who underwent hepatectomy for HCC with extrahepatic metastases, including lymph node and/or distant metastases were recruited for this study.

RESULTS

Fourteen patients had lymph node metastasis only, 16 had distant metastasis only, and 2 had both metastasis types during preoperative diagnosis. The 3-year overall survival (OS) rate of all patients was 17.9%, and the median survival time (MST) was 11.8 months. Univariate analysis revealed that intrahepatic maximal tumor size, intrahepatic tumor number, and intrahepatic tumor control after hepatectomy were significant factors influencing OS (p < 0.05). Multivariate analysis revealed that independent risk factors for OS were intrahepatic maximal tumor size and intrahepatic tumor number (p < 0.05). The MST and 3-year OS rate of patients with maximal tumor size <100 mm and intrahepatic tumor number ≤2 were 39.0 months and 51.9%, respectively.

CONCLUSIONS

Hepatectomy is not recommended for HCC patients with extrahepatic metastasis with ≥3 intrahepatic tumors, even when all intrahepatic tumors can be eliminated via hepatectomy. Aggressive surgery may be justified for HCC patients with ≤2 intrahepatic tumors and maximal tumor size <100 mm, irrespective of vascular invasion.

摘要

背景

本研究评估了可接受肝切除术的合并肝外转移的肝细胞癌(HCC)患者的预后。

方法

共纳入 32 例术前诊断为合并淋巴结和/或远处转移的 HCC 患者行肝切除术。

结果

14 例患者仅存在淋巴结转移,16 例患者仅存在远处转移,2 例患者术前诊断同时存在两种转移类型。所有患者的 3 年总生存率(OS)为 17.9%,中位生存时间(MST)为 11.8 个月。单因素分析显示,肝内最大肿瘤直径、肝内肿瘤数量和肝切除术后肝内肿瘤控制情况是影响 OS 的显著因素(p<0.05)。多因素分析显示,OS 的独立危险因素是肝内最大肿瘤直径和肝内肿瘤数量(p<0.05)。最大肿瘤直径<100mm 和肝内肿瘤数量≤2 的患者 MST 和 3 年 OS 率分别为 39.0 个月和 51.9%。

结论

对于合并≥3 个肝内肿瘤的 HCC 患者,即使所有肝内肿瘤均可通过肝切除术消除,也不建议行肝切除术。对于最大肿瘤直径<100mm 且肝内肿瘤数量≤2 的 HCC 患者,无论是否存在血管侵犯,积极手术可能是合理的。

相似文献

1
Clinical Significance of Hepatectomy for Hepatocellular Carcinoma Associated with Extrahepatic Metastases.肝癌伴肝外转移行肝切除术的临床意义。
Dig Surg. 2020;37(5):411-419. doi: 10.1159/000507436. Epub 2020 May 26.
2
Treatment for extrahepatic metastasis of hepatocellular carcinoma following successful hepatic resection.肝切除成功后肝细胞癌肝外转移的治疗
Hepatogastroenterology. 1999 Sep-Oct;46(29):2931-4.
3
[A new prognostic score system of hepatocellular carcinoma following hepatectomy].[一种肝切除术后肝细胞癌的新预后评分系统]
Zhonghua Zhong Liu Za Zhi. 2017 Dec 23;39(12):903-909. doi: 10.3760/cma.j.issn.0253-3766.2017.12.005.
4
Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions.肝细胞癌肝外转移患者的预后及肝内病灶的可控性
Clin Exp Metastasis. 2014 Apr;31(4):475-82. doi: 10.1007/s10585-014-9641-x. Epub 2014 Feb 5.
5
Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.肝细胞癌伴肝外转移:临床特征和预后因素。
Cancer. 2011 Oct 1;117(19):4475-83. doi: 10.1002/cncr.25960. Epub 2011 Mar 22.
6
Clinical features of hepatocellular carcinoma with extrahepatic metastases.伴有肝外转移的肝细胞癌的临床特征。
J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7. doi: 10.1111/j.1440-1746.2005.03919.x.
7
Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma.根治性肝切除术后肝细胞癌肝外复发的预测因素。
Ann Surg Oncol. 2010 Oct;17(10):2740-6. doi: 10.1245/s10434-010-1076-2. Epub 2010 Apr 22.
8
Percutaneous treatment of extrahepatic recurrence of hepatocellular carcinoma.肝细胞癌肝外复发的经皮治疗
Diagn Interv Imaging. 2016 Nov;97(11):1117-1123. doi: 10.1016/j.diii.2015.11.020. Epub 2016 Apr 29.
9
Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence.复发性肝细胞癌的外科治疗结果;多中心癌变、肝内转移和肝外复发患者的预后比较。
J Hepatobiliary Pancreat Surg. 1998;5(1):86-92. doi: 10.1007/pl00009956.
10
Pulmonary metastasectomy for hepatocellular carcinoma.肝细胞癌的肺转移瘤切除术
J Chin Med Assoc. 2004 Dec;67(12):621-4.

引用本文的文献

1
Treatment outcomes of hepatectomy and systemic chemotherapy based on oncological resectability criteria for hepatocellular carcinoma.基于肝细胞癌肿瘤可切除性标准的肝切除术和全身化疗的治疗效果。
Ann Gastroenterol Surg. 2024 Dec 20;9(2):235-243. doi: 10.1002/ags3.12893. eCollection 2025 Mar.
2
Survival Prediction Model for Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis Based on XGBoost Algorithm.基于XGBoost算法的肝细胞癌合并肝外转移患者生存预测模型
J Hepatocell Carcinoma. 2023 Dec 13;10:2251-2263. doi: 10.2147/JHC.S429903. eCollection 2023.